The Biggest Indian Pharma Deal of the Decade

Since late May 2026, Maharashtra has been in the middle of one of its most aggressive food and drug enforcement drives in years — adulterated prasad seized near Shirdi, synthetic milk units shut down, the license of Mumbai’s Parsi Dairy Farm suspended, hospitals pulled up for for ...  Show more

In this conversation with ET's editor technology Surabhi Agarwal, Google Cloud CEO Thomas Kurian discusses the company's expanding footprint in India, including bringing Gemini Flash 3.5 and Gemini Enterprise to sovereign infrastructure, and scaling local engineering talent throu ...  Show more

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. \u0010 \u0010GUEST: \u0010Cynthia Koons \u0010Health Care Reporter \u0010Bloomberg Editorial \u0010on Pfizer beating out rivals to buy biopharmaceutical company, Medivation, and its blockbuster cancer drug for $14 billi ...  Show more

In the past month pharmaceutical companies have spent almost $100bn acquiring biotech companies. The FT's Sarah Neville explains why big pharma is raising its bet on the drug pipelines owned by biotechs, and why analysts expect more consolidation in 2019. 

Read ...

Bloomberg’s Caroline Hyde and Ed Ludlow discuss Electronic Arts’ agreement to be sold in a record-breaking leveraged buyout. Plus, Huawei plans to ramp up production of its most advanced AI chips in a bid to take market share from Nvidia. And Peloton is preparing to launch new AI ...  Show more

Jim Cramer and David Faber breakdown M&A Monday. A busy morning in deal news, starting with a historic deal in the chip sector. Nvidia buying Arm from Softbank in a deal valued at $40 billion financed through a combination of cash and common stock. Nvidia CEO, Jensen Huang, jo ...